U.S. markets closed
  • S&P 500

    +11.90 (+0.34%)
  • Dow 30

    -28.09 (-0.10%)
  • Nasdaq

    +42.28 (+0.37%)
  • Russell 2000

    +10.25 (+0.63%)
  • Crude Oil

    -0.86 (-2.12%)
  • Gold

    -1.20 (-0.06%)
  • Silver

    -0.01 (-0.04%)

    +0.0042 (+0.36%)
  • 10-Yr Bond

    -0.0070 (-0.83%)

    -0.0042 (-0.32%)

    -0.1200 (-0.11%)

    +86.82 (+0.67%)
  • CMC Crypto 200

    -1.40 (-0.54%)
  • FTSE 100

    +74.63 (+1.29%)
  • Nikkei 225

    +42.32 (+0.18%)

SmallCap Sentinel: From Harvard to Hemp, a Journey to Colombia

ORLANDO, FL / ACCESSWIRE / February 13, 2019 / In a recent interview, leading cannabis-testing lab and data firm Digipath Inc. (DIGP) CEO, Todd Denkin, expanded on his company's intent to build a presence in the Colombian cannabis market, a market that many believe will be among the most significant cannabis producers in the world.

Denkin's quote was as follows: ''About ten years ago when pot stocks first entered into the marketplace and cannabis stocks started appearing on NASDAQ, that had a huge impact on the stock market and had a huge impact on the economy. Well, we see Colombia affecting the cannabis market the same way cannabis affected the stock market.''

''Colombia is going to be a huge player and is already beginning large scale production.'' (Click here for the full interview)

Plainly put, Digipath isn't waiting around to secure its place in Colombia. The Company is aggressively pursuing opportunities in the South American nation, adding to its interests with a quality hire just yesterday. While most Americans won't know the name of the head of Digipath's new Colombian venture, his resume should certainly turn heads.

Jorge Restrepo's appointment on Monday provides Digipath with a tremendous advocate in his native nation of Colombia where he can leverage a lifetime of relationships to help install Digipath as a Colombian cannabis-testing leader. It is also imperative to note that the veteran Colombian agronomist adds to an already impressive c-suite of leadership inside Digipath a Masters Degree in Public Administration from Harvard University, The Kennedy School of Government.

It should say something, and not quietly, that a Colombian national, veteran agronomist, educated at arguably the finest school of its kind in the world is now Digipath's man in Colombia.

About Digipath, Inc. & Digipath Labs, Inc.

Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.

For more information on Digipath visit the links below:



About SmallCap Sentinel:

SmallCap Sentinel is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php.

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

EMC has been paid 30,000 dollars by Digipath Labs for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. A contributor to this report holds 400,000 shares and receives $3,500 a month for a period of six months for investor relations services on the behalf of Digipath.



Emerging Markets Consulting, LLC
Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com

SOURCE: Emerging Markets Report

View source version on accesswire.com: